To hear about similar clinical trials, please enter your email below
Trial Title:
Evaluation of CMV/EBV-CMI in Haploid HSCT
NCT ID:
NCT06554197
Condition:
Hematopoietic Stem Cell Transplantation
Cytomegalovirus Infections
Epstein-Barr Virus Infections
Conditions: Official terms:
Infections
Communicable Diseases
Cytomegalovirus Infections
Epstein-Barr Virus Infections
Study type:
Observational
Overall status:
Recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Diagnostic Test
Intervention name:
CMV/EBV-CMI
Description:
The CMV/EBV-CMI is tested before conditioning regimen and 30 days, 45 days, 60 days, 90
days, 120 days, 180 days after transplantation.
Summary:
The purpose of this prospective, open-label, Single Arm, single-center study is to
evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for
patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid
hematopoietic stem cell transplantation(haplo-HSCT) .
Criteria for eligibility:
Study pop:
Patients are diagnosed with hemopathy and should have the indication of Haploidentical
hematopoietic stem cell transplant and receive the prophylaxis for cytomegalovirus.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
1. All patients were diagnosed with hemopathy.
2. All patients should have the indication of Haploidentical hematopoietic stem cell
transplant and receive the prophylaxis for cytomegalovirus.
3. All patients should sign an informed consent document indicating that they
understand the purpose of and procedures required for the study and be willing to
participate in the study.
Exclusion Criteria:
Patients with any conditions not suitable for the trial (investigators' decision).
Gender:
All
Minimum age:
16 Years
Maximum age:
60 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
First Affiliated Hospital of Soochow University
Address:
City:
Suzhou
Zip:
215006
Country:
China
Status:
Recruiting
Contact:
Last name:
Feng Chen, PhD
Phone:
13584861215
Email:
13584861215@163.com
Start date:
August 13, 2024
Completion date:
July 31, 2026
Lead sponsor:
Agency:
The First Affiliated Hospital of Soochow University
Agency class:
Other
Source:
The First Affiliated Hospital of Soochow University
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06554197
